Industrials
Live Price
Offline$3.38
+0.00% today
1Y Change
+2.29%
Window
Jun 26, 2025 โ Jun 24, 2026
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Atlas Arteria Limited (MAQAF) is a Industrials stock with a market cap of $6.96B and listed on OTC. The stock last traded around $3.38 and up 2.3% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +10.3%, EPS growth of -21.7%, a dividend yield of 8.3%. What stands out right now is revenue +10.3%, EPS -21.7%, free cash flow +565.8% with operating margin 9.4% and ROIC 0.1%. The dividend matters to the case here, with a current yield around 8.3%. Valuation already assumes a fairly strong business story at P/E 33.8 and price/sales 57.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MAQAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.3% vs +6.8% peer median
Operating Margin
Below sector median
+9.4% vs +16.9% peer median
P/E
Below sector median
33.8 vs 36.7 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 25, 2026 with an EPS surprise of -1.4% and a revenue surprise of -41.2%.
The operating picture looks softer than before
Revenue is at +10.3% and EPS is at -21.7%, with operating margin around 9.4%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.9% over the next 5 trading days and finished higher after 0 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 25, 2026 | -1.4% | +0.0% | -2.7% | -12.5% |
2025 Aug 27, 2025 | -59.6% | +0.0% | +0.0% | +1.4% |
2025 Feb 27, 2025 | -43.5% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MAQAF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MAQAF Max Drawdown
-24.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for MAQAF and SPY.

Company Overview
Atlas Arteria Limited
Other OTC
Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 13.4% interest in 22-kilometer toll road investors partnership II (TRIP II), the concessionaire for Dulles Greenway toll road located in Virginia, the United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.